A Randomized, Crossover, Single-Dose Bioequivalence Study of Two Extended Release Tablets of Donepezil 23 mg in Healthy Human Volunteers under Fasting and Fed State
Open Access
- 1 January 2013
- journal article
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 81 (3) , 777-791
Abstract
To assess the bioequivalence of two extended-release tablets of donepezil 23 mg, open label, randomized, single-dose, two-sequence, two-period cross-over studies under fasting (n=74) and fed (n=94) conditions in healthy adult human volunteers were conducted. Subjects were randomized to either of the two treatment arms (test or reference) separated by a washout period of 28 days. Blood samples were collected up to 72 h post-dose and plasma samples were analyzed for donepezil using a validated LC-MS/MS method. Pharmaco-kinetic parameters were derived using a non-compartmental approach. Bioequivalence was evaluated in 69 subjects in the fasting study, and 71 subjects in the fed study. In the fasting study, the 90% CI of Cmax and AUC0-72 were 82.50–90.10 and 92.38–98.60, respectively. Corresponding values in the fed study were 91.82–98.05 and 97.27–100.27. Based on the results, the test product (donepezil) met the US regulatory criteria of bioequivalence relative to the reference product (Aricept®) under both fasting and fed conditions.Keywords
This publication has 17 references indexed in Scilit:
- Transdermal donepezil on the treatment of Alzheimer's diseaseNeuropsychiatric Disease and Treatment, 2012
- National estimates of the prevalence of Alzheimer's disease in the United StatesAlzheimer's & Dementia, 2011
- Bioequivalence study of two different tablet formulations of donepezil using truncated areas under the curveArzneimittelforschung, 2010
- The Use of Truncated Area under the Curves in the Bioequivalence Evaluation of Long Half-Life DrugsArzneimittelforschung, 2008
- Liquid Chromatography-Electrospray Ionization Ion Trap Mass Spectrometry for Analysis of in Vivo and in Vitro Metabolites of Scopolamine in RatsJournal of Chromatographic Science, 2008
- The safety and tolerability of donepezil in patients with Alzheimer's diseaseBritish Journal of Clinical Pharmacology, 2004
- Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase InhibitorsClinical Pharmacokinetics, 2002
- Rivastigmine, a New‐Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's DiseasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
- Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral dosesBritish Journal of Clinical Pharmacology, 1998
- Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer TypeNew England Journal of Medicine, 1986